清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

SMART START: RITUXIMAB, LENALIDOMIDE, AND IBRUTINIB ALONE PRIOR TO COMBINATION WITH CHEMOTHERAPY FOR PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA

作者
J.R. Westin,L. Nastoupil,F. Hagemeister,Luis Fayad,K. Young,Timothy J. McDonnell,H. Chuang,Shimaa Abdallah Ahmed,Ranjit K. Nair,Raphael Eric Steiner,H. Lee,M. Rodriguez,S. Parmar,M. Green,Sattva Swarup Neelapu,R. Eric Davis
出处
期刊:Hematological Oncology [Wiley]
卷期号:37 (S2): 78-79 被引量:2
标识
DOI:10.1002/hon.48_2629
摘要

Background: The non-germinal center (non-GCB) subtype of Diffuse Large B-cell Lymphoma (DLBCL) is associated with inferior outcomes with standard therapies. The BTK inhibitor ibrutinib (I) and immunomodulatory agent lenalidomide (L) have promising activity in non-GCB DLBCL as single agents, and result in synthetic lethality in non-GCB DLBCL models when combined. In relapsed non-GCB DLBCL, rituximab (R), L and I result in overall response rate (ORR) of 55% (Ramchandren, ASH 2018). We conducted an investigator initiated, single-arm, open-label, phase 2 study (NCT02636322) of RLI alone and then with chemotherapy in newly diagnosed non-GCB DLBCL patients, and report the final results of the RLI lead in. Methods: Adult patients with newly diagnosed non-GCB DLBCL, determined by the Hans method, with adequate organ function and performance status were eligible. The primary objectives were to determine (1A) the ORR of two cycles of RLI as initial therapy, and (1B) the complete response rate (CRR) after 6 cycles of chemotherapy combined with RLI. All patients were treated with rituximab 375 mg/m2 IV day 1, ibrutinib 560 mg po daily, and lenalidomide 25 mg po days 1-10 of 21 day cycles for 2 cycles, followed by 6 additional cycles of RLI with chemotherapy (CHOP or EPOCH per treating MD choice). Responses were assessed with PET/CT as per the Lugano criteria. Growth factors, venous thromboembolism prophylaxis, and pneumocystis pneumonia prophylaxis were required for all patients. Results: The protocol accrued 60 patients from May 2016 – February 2019, with 52 patients evaluable for disease response (2 withdrew consent prior to restaging, 6 pending restaging prior to abstract deadline). The median age was 64 years (range: 30-83), 28% were >= 70 years, and 50% were female. Half the patients had poor risk IPI, 61% had advanced stage, and 71% had a Ki-67 of >= 80%. One patient had a fatal fungal infection (CNS aspergillosis) attributed to high dose corticosteroids for symptom control during screening and with RLI, leading to prohibition of corticosteroids during the RLI only cycles with no further fungal infections identified. The ORR for 2 cycles of RLI alone was 84.6% (n = 44), and the CRR was 38.5% (n = 20). One patient refused to proceed with the pre-planned chemotherapy after achieving a CR with 2 cycles of RLI, and remains relapse free with no additional therapy 18 months later. Preliminary results demonstrate a CRR of 100% for the full therapy (RLI for 2 cycles, RLI-chemo for 6 cycles), with updates to be presented at the meeting. Conclusions: The Smart Start trial demonstrates the chemotherapy-free combination of rituximab 375 mg/m2, ibrutinib 560 mg, and lenalidomide 25mg is highly effective in patients with newly diagnosed non-GCB DLBCL. Further studies are planned with other novel agents and with fewer cycles of chemotherapy consolidation for patients achieving a CR with RLI alone. Keywords: activated B-cell-like (ABC); BTK inhibitors; IMiDs. Disclosures: Westin, J: Consultant Advisory Role: Celgene, Janssen, Novartis, Kite, Juno, Genentech.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
光亮的幻桃完成签到,获得积分10
9秒前
18秒前
hy完成签到,获得积分10
20秒前
nano完成签到 ,获得积分10
29秒前
RZH发布了新的文献求助10
38秒前
机智的如曼完成签到,获得积分10
48秒前
Xzx1995完成签到 ,获得积分10
50秒前
FashionBoy的应助被科研通管家采纳,获得10
53秒前
fairytaler的应助被科研通管家采纳,获得10
53秒前
现代的初之完成签到,获得积分10
59秒前
大模型的应助被蜗牛好好飞采纳,获得10
1分钟前
ChatGPT完成签到,获得积分10
1分钟前
慕青的应助被蜗牛好好飞采纳,获得10
1分钟前
夏同学完成签到 ,获得积分10
1分钟前
今后的应助被蜗牛好好飞采纳,获得10
1分钟前
wwrjj完成签到,获得积分0
1分钟前
搜集达人的应助被cc采纳,获得10
1分钟前
大模型的应助被蜗牛好好飞采纳,获得10
1分钟前
1分钟前
1分钟前
御坂10576号完成签到,获得积分10
1分钟前
1分钟前
义气的雅琴完成签到,获得积分10
1分钟前
cc发布了新的文献求助10
1分钟前
NexusExplorer的应助被蜗牛好好飞采纳,获得10
1分钟前
Harlotte完成签到 ,获得积分0
1分钟前
蒋不惜完成签到,获得积分10
1分钟前
changfox完成签到,获得积分10
1分钟前
hyk完成签到 ,获得积分10
1分钟前
milalala完成签到 ,获得积分10
1分钟前
浚稚完成签到 ,获得积分10
1分钟前
1分钟前
冷傲的夜白完成签到,获得积分10
1分钟前
岳晓燕完成签到 ,获得积分10
1分钟前
1分钟前
清脆代真发布了新的文献求助50
1分钟前
2分钟前
谭访冬完成签到,获得积分10
2分钟前
MUAN完成签到 ,获得积分10
2分钟前
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173230
求助须知:如何正确求助?哪些是违规求助? 9565593
关于积分的说明 21780525
捐赠科研通 7767429
什么是DOI,文献DOI怎么找? 3431542
关于科研通互助平台的介绍 2555764
邀请新用户注册赠送积分活动 2476697